Neonc Technologies Holdings, Inc. (NTHI) Stock

Neonc Technologies Holdings, Inc. (NTHI) is a Healthcare stock trading at $5.35 (as of 2026-06-18), with a market capitalization of $120.70M and a trailing P/E of -3.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neonc Technologies Holdings, Inc. develops molecular technologies aimed at improving targeted delivery of therapeutic payloads for central nervous system diseases. Its pipeline includes NEO100, in Phase 2a clinical trials for glioblastoma, and NEO212, a covalently conjugated molecule combining temozolomide with perillyl alcohol that has completed preclinical testing.

Valuation — source: SEC EDGAR (first-party)
Price	$5.35
Market Cap	$120.70M
P/E Ratio	-3.1
Price / Book	-9.12
Price / Sales	3018.28
DCF Value (model)	$-14.04
DCF Upside vs Price	-362.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$39990.00
Net Margin	-155404.4%
Return on Equity	249.1%
Current Ratio	0.13
Revenue Growth (YoY)	-51.8%
EPS Growth (YoY)	363.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-127.89 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-115.0%
vs Industry	-118.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Cinctive Capital Management LP ($9.99M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Amir Farrokh Heshmatpour
Employees	8
Country	US
IPO Date	2025-03-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.